Jonathan Chang, an analyst from Leerink Partners, reiterated the Buy rating on NovoCure (NVCR – Research Report). The associated price target remains the same with $33.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Jonathan Chang’s rating is based on NovoCure’s strong financial performance and promising pipeline developments. The company reported first-quarter 2025 revenues of $155.0 million, surpassing consensus estimates, largely due to growth in active patient numbers and improved reimbursement rates. This financial success underscores the company’s robust market presence and operational efficiency.
Additionally, the recent approval of Optune Lua in Europe and its early success in non-small cell lung cancer prescriptions indicate significant growth potential. The upcoming presentation of the Phase III PANOVA-3 trial results at a major oncology conference is anticipated to be a key catalyst for the stock. These factors, combined with a positive outlook on regulatory decisions and the company’s strategic milestones, contribute to the Buy rating for NovoCure.
In another report released on April 24, H.C. Wainwright also maintained a Buy rating on the stock with a $38.00 price target.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NVCR in relation to earlier this year.